Literature DB >> 23850262

Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort.

Alicia J Jenkins1, Jeremy Yu, Petar Alaupovic, Arpita Basu, Richard L Klein, Maria Lopes-Virella, Nathaniel L Baker, Kelly J Hunt, Daniel T Lackland, W Timothy Garvey, Timothy J Lyons.   

Abstract

AIMS: Dyslipoproteinemia has been associated with nephropathy in diabetes, with stronger correlations in men than in women. We aimed to characterize and compare plasma lipoprotein profiles associated with normal and increased albuminuria in men and women using apolipoprotein-defined lipoprotein subclasses and simple apolipoprotein measures.
METHODS: This is a cross-sectional study in a subset (154 women and 282 men) of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort, using samples obtained in 1997-9. Immunochemical methods were used to quantify plasma apolipoprotein-based lipoprotein subclasses and individual apolipoprotein levels.
RESULTS: In adjusted analyses, elevated Lipoprotein-B (Lp-B) was significantly associated with macroalbuminuria in men [odds ratios (OR) and 95% confidence interval (CI): 2.13 (1.15-3.97)] and women [3.01 (1.11-8.12)], while association with Lp-B:C was observed only in men [1.84 (1.19-2.86)]. For individual apolipoproteins the following significant associations with macroalbuminuria were observed in men only: Apolipoprotein B (ApoB) [1.97 (1.20-3.25)], Apo-AII [0.52 (0.29-0.93)], ApoC-III [1.95 (1.16-3.30)], "ApoC-III in VLDL" (heparin-manganese precipitate) [1.88 (1.16-3.04)], and "ApoCIII in HDL" (heparin-manganese supernatant) [2.03 (1.27-3.26)], all P<0.05).
CONCLUSIONS: Atherogenic apolipoprotein-based profiles are associated with nephropathy in Type 1 diabetic men and to a lesser extent in women. The difference could result from the greater prevalence and severity of dyslipoproteinemia, and from the greater prevalence of renal dysfunction, in men vs women.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Albuminuria; Apolipoproteins; Lipoproteins; Nephropathy; Type 1 diabetes

Mesh:

Substances:

Year:  2013        PMID: 23850262      PMCID: PMC4064461          DOI: 10.1016/j.jdiacomp.2013.06.002

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  48 in total

1.  Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity.

Authors:  Shalamar D Sibley; William Thomas; Ian de Boer; John D Brunzell; Michael W Steffes
Journal:  Am J Kidney Dis       Date:  2006-02       Impact factor: 8.860

2.  Nuclear magnetic resonance-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with carotid intima-media thickness.

Authors:  T J Lyons; A J Jenkins; D Zheng; R L Klein; J D Otvos; Y Yu; D T Lackland; D McGee; M B McHenry; M Lopes-Virella; W T Garvey
Journal:  Diabet Med       Date:  2006-09       Impact factor: 4.359

3.  Proteome analysis of serum from type 2 diabetics with nephropathy.

Authors:  Hyun-Jung Kim; Eun-Hee Cho; Ji-Hye Yoo; Pan-Kyeom Kim; Jun-Seop Shin; Mi-Ryung Kim; Chan-Wha Kim
Journal:  J Proteome Res       Date:  2007-02       Impact factor: 4.466

4.  Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study.

Authors:  Ian H de Boer; Shalamar D Sibley; Bryan Kestenbaum; Joshua N Sampson; Bessie Young; Patricia A Cleary; Michael W Steffes; Noel S Weiss; John D Brunzell
Journal:  J Am Soc Nephrol       Date:  2006-12-06       Impact factor: 10.121

Review 5.  An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?

Authors:  D C Chan; M M Chen; E M M Ooi; G F Watts
Journal:  Int J Clin Pract       Date:  2008-01-14       Impact factor: 2.503

6.  Postprandial effect of n-3 polyunsaturated fatty acids on apolipoprotein B-containing lipoproteins and vascular reactivity in type 2 diabetes.

Authors:  Kirsten F Hilpert; Sheila G West; Penny M Kris-Etherton; Kari D Hecker; Nancy M Simpson; Petar Alaupovic
Journal:  Am J Clin Nutr       Date:  2007-02       Impact factor: 7.045

Review 7.  Management of dyslipidemias in patients with diabetes and chronic kidney disease.

Authors:  Mark E Molitch
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-26       Impact factor: 8.237

8.  Connective tissue growth factor and susceptibility to renal and vascular disease risk in type 1 diabetes.

Authors:  Ayad A Jaffa; William R Usinger; M Brent McHenry; Miran A Jaffa; Stuart R Lipstiz; Daniel Lackland; Maria Lopes-Virella; Louis M Luttrell; Peter W F Wilson
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

Review 9.  Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.

Authors:  Esther M M Ooi; P Hugh R Barrett; Dick C Chan; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2008-05       Impact factor: 6.124

Review 10.  Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?

Authors:  Ted Wu; Kristine C Y McGrath; Alison K Death
Journal:  Vasc Health Risk Manag       Date:  2005
View more
  4 in total

Review 1.  Glucose targets for preventing diabetic kidney disease and its progression.

Authors:  Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

2.  Is it time to change the goals of lipid management in type 1 diabetes mellitus? Changes in apolipoprotein levels during the first year of type 1 diabetes mellitus. Prospective InLipoDiab1 study.

Authors:  Aleksandra Cieluch; Aleksandra Uruska; Marcin Nowicki; Ewa Wysocka; Paweł Niedźwiecki; Agata Grzelka-Woźniak; Justyna Flotyńska; Dorota Zozulińska-Ziółkiewicz
Journal:  Arch Med Sci       Date:  2020-10-29       Impact factor: 3.707

3.  Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D.

Authors:  Arpita Basu; Alicia J Jenkins; Julie A Stoner; Ying Zhang; Richard L Klein; Maria F Lopes-Virella; W Timothy Garvey; David S Schade; Jamie Wood; Petar Alaupovic; Timothy J Lyons
Journal:  J Lipid Res       Date:  2018-03-25       Impact factor: 5.922

Review 4.  Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.

Authors:  Clement Lo; Tadashi Toyama; Ying Wang; Jin Lin; Yoichiro Hirakawa; Min Jun; Alan Cass; Carmel M Hawley; Helen Pilmore; Sunil V Badve; Vlado Perkovic; Sophia Zoungas
Journal:  Cochrane Database Syst Rev       Date:  2018-09-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.